Company

Medigene (FSE: MDG1) is a publicly listed, immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. 

TCR-T expertise is the foundation for our integrated proprietary End-to-End Platform which includes multiple TCR generation and optimization technologies as well as product enhancement technologies.

differentiated approach addresing current
tcr-t therapy challenges 

Suboptimal Target Interaction

Low specificity, low/high affinity, low avidity
➣ Reduced efficacy & safety

Immunosuppressive TME

Poor penetration, persistence of T cells, lack of proliferation
➣ Reduced efficacy & durability

Inadequate DP Composition

Lack of proliferation, functionality and sub-optimal cell composition
➣ Reduced efficacy, safety & durability

Optimal Affinity TCRs

✓ Young, healthy donors with broad TCR repertoires
✓ Sensitive, specific and safe (3S) attributes for improved clinical safety & efficacy

CSP Armoring & Enhancement

✓ Improved TME penetration
✓ Enhanced proliferation / persistence overcome TME immunosuppression to enhance clinical efficacy

Tailored DP Composition

✓ Accelerated 6-day automated GMP manufacturing
✓ ~20-day vein-to-vein time
✓ CD8+ DP characteristics with high proportion of Tscm / Tcm to improve clinical efficacy & safety and durability

TME; Tumor microenvironment, CSP: Costimulatory switch protein, DP; Drug Product

Company Strategy

Medigene’s strategy is to develop its therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the company offers selected partners the opportunity to discover and develop additional therapies by accessing Medigene’s proprietary End-to-End Platform that includes optimization technologies (like our Allo-HLA priming) and enhancement technologies (like our PD1-41BB and CD40L-CD28 costimulatory switch proteins).

Focus on T-cell-directed immunotherapies

Focus on T-cell-directed immunotherapies

About 80 employees with expertise in immunotherapy and pharmaceutical development

About 80 employees with expertise in immunotherapy and pharmaceutical development

Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California

Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California

Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00

Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00

Company History

Medigene announces priorization of pipeline and resource allocation
Pipeline expansion into neoantigens with programs targeting multiple KRAS mutations and HLAs
Medigene announces strategy and corporate update
Comprehensive research and development partnership with BioNTech
Publication of topline data of the Phase I/II study of MDG1011 in AML and MDS
Publication of topline data of the DC vaccine trial (FDC101)
Sale of remaining rights and inventories of Veregen®
Roivant and Sinovant launch Cytovant Sciences in partnership with Medigene to develop cellular therapies in Asia
Start of the Phase I/II study of MDG1011 in AML and MDS
Expansion of the bluebird bio partnership
U.S.-rights for Veregen® are disposed
bluebird bio and Medigene establish strategic T cell receptor alliance in cancer immunotherapy
Start of Phase II part of the clinical trial with DC vaccine (FDC101)
Amgen acquires Medigene spin-off Catherex
Start of Phase I/II clinical trial with DC vaccine (FDC101) to treat AML
Focus on immuno-oncology by acquisition of Trianta Immunotherapies (renamed Medigene Immunotherapies)
Strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex®
Medigene’s product Veregen® became the first FDA-approved biopharmaceutical of a German biotech company in the USA
Medigene acquired British biotechnology company Avidex Limited
Medigene received first regulatory approval for cancer drug Eligard® in Germany
Medigene acquired products and technology of Munich Biotech AG
Medigene acquired US biotechnology company NeuroVir
Medigene IPO listed on the Frankfurt Stock Exchange
Medigene founded as Munich Gene Center spin-off
2023
2023
2022
2022
2021
2020
2019
2019
2018
2018
2017
2016
2016
2015
2015
2014
2012-2014
2006
2006
2004
2004
2001
2000
1994